De-risk & accelerate the drug development process for gene therapy
The BioInsights Podcast
More Info
The BioInsights Podcast
De-risk & accelerate the drug development process for gene therapy
Sep 29, 2022 Season 1 Episode 17
Dr Kim Watanabe

In today’s challenging financial environment, it is more important than ever to get key biotech business decisions right first time. One of the most important and topical of these is the choice of CDMO partner. Dr Kim Watanabe, General Manager and Site Head for Patheon Translational Services, a part of the Thermo Fisher Scientific pharma services contract development and manufacturing organizational arm, joins BioInsights to share her advice and insights into optimizing outsourcing strategy.